CN120441567A - Chk1抑制剂的合成方法 - Google Patents

Chk1抑制剂的合成方法

Info

Publication number
CN120441567A
CN120441567A CN202510460667.8A CN202510460667A CN120441567A CN 120441567 A CN120441567 A CN 120441567A CN 202510460667 A CN202510460667 A CN 202510460667A CN 120441567 A CN120441567 A CN 120441567A
Authority
CN
China
Prior art keywords
compound
substituted
formula
compounds
impurities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510460667.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·施维伯
T·罗斯纳
D·赵
R·米勒
R·杜利纳
M·胡莫拉
S·E·戈特施林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRT Pioneer Fund LP
Original Assignee
CRT Pioneer Fund LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRT Pioneer Fund LP filed Critical CRT Pioneer Fund LP
Publication of CN120441567A publication Critical patent/CN120441567A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202510460667.8A 2020-04-07 2021-04-06 Chk1抑制剂的合成方法 Pending CN120441567A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063006305P 2020-04-07 2020-04-07
US63/006,305 2020-04-07
CN202180027747.4A CN115443271A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法
PCT/US2021/025977 WO2021207210A1 (en) 2020-04-07 2021-04-06 Methods for synthesis of chk1 inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180027747.4A Division CN115443271A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法

Publications (1)

Publication Number Publication Date
CN120441567A true CN120441567A (zh) 2025-08-08

Family

ID=78024095

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510460667.8A Pending CN120441567A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法
CN202180027747.4A Pending CN115443271A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180027747.4A Pending CN115443271A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法

Country Status (7)

Country Link
US (2) US12606550B2 (cg-RX-API-DMAC7.html)
EP (1) EP4132922A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023523165A (cg-RX-API-DMAC7.html)
CN (2) CN120441567A (cg-RX-API-DMAC7.html)
BR (1) BR112022020278A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174222A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021207210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法
WO2026108769A1 (en) * 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP4637481B2 (ja) 2001-10-19 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
CA2464934A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003243318A1 (en) 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2004260689B8 (en) 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005034869A2 (en) 2003-10-08 2005-04-21 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005037825A2 (en) 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
WO2005037285A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US7642354B2 (en) 2004-04-13 2010-01-05 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
CN1243033C (zh) 2004-07-15 2006-02-22 合肥工业大学 一种通过内增韧制备薄膜级聚l-乳酸共聚物的方法
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101189239A (zh) 2005-04-28 2008-05-28 休普基因公司 蛋白激酶抑制剂
EP1899322B1 (en) 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
PE20070543A1 (es) 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0616747D0 (en) 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
AU2007338410B2 (en) 2006-12-27 2012-08-16 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
EP2134689B1 (en) 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
RU2009147819A (ru) 2007-05-25 2011-06-27 Астразенека Аб (Se) Комбинация ингибиторов снк и parp для лечения злокачественных новообразований
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009099601A2 (en) 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US8865726B2 (en) * 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
CA2860665A1 (en) 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
JP6027230B2 (ja) * 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用
CN102675858A (zh) 2012-05-22 2012-09-19 同济大学 一种具有形状记忆功能可降解泪管栓塞的制备方法
GB201316526D0 (en) 2013-09-17 2013-10-30 King S College London Biomarkers
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
SG10201913151TA (en) 2015-09-09 2020-03-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Genetic engineering of macrophages for immunotherapy
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
WO2018191299A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
MX2019012176A (es) 2017-04-10 2020-02-19 Sierra Oncology Inc Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
AU2018278336A1 (en) 2017-06-01 2020-01-16 Crt Pioneer Fund Lp Biomarkers and patient selection strategies
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
JP2021514979A (ja) 2018-02-26 2021-06-17 シエラ オンコロジー, インコーポレイテッド Chk1阻害剤を含む癌の治療方法
CA3135165A1 (en) 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
AU2020274164A1 (en) 2019-05-14 2021-11-25 Sierra Oncology, Inc. Methods of treating cancer using Chk1 inhibitors
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法

Also Published As

Publication number Publication date
US20230150994A1 (en) 2023-05-18
EP4132922A1 (en) 2023-02-15
JP2023523165A (ja) 2023-06-02
US12606550B2 (en) 2026-04-21
CN115443271A (zh) 2022-12-06
CA3174222A1 (en) 2021-10-14
WO2021207210A1 (en) 2021-10-14
TW202204348A (zh) 2022-02-01
EP4132922A4 (en) 2024-07-03
JP2026097919A (ja) 2026-06-16
US20260217695A1 (en) 2026-07-30
BR112022020278A2 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
AU2019260159B2 (en) HPK1 inhibitors, preparation method and application thereof
EP3080121B1 (en) Fused tricyclic benzimidazoles derivatives as modulators of tnf activity
JP2022530383A (ja) キナゾリン化合物及びその医薬上の使用
JP7797486B2 (ja) 新規なrho関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
JP2023553297A (ja) Trpm3媒介性障害を治療するための複素環誘導体
TW202102509A (zh) 靶向prmt5之化合物
CN111343988A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
KR20180005248A (ko) 복소환형 화합물의 합성
CN115380036A (zh) Sstr5拮抗剂
JP2006515334A (ja) CRF受容体アンタゴニストとしてのヘテロアリール置換ピロロ[2,3−b]ピリジン誘導体
WO2020073011A1 (en) Compounds and compositions for treating conditions associated with apj receptor activity
WO2020254552A2 (en) Substituted pyrrolidine amides v
EP3083628B1 (en) Fused imidazolyl derivatives, their preparation and use as medicaments
US12435086B2 (en) Synthesis of heterocyclic compounds
US12606550B2 (en) Methods for synthesis of CHK1 inhibitors
JP6074775B2 (ja) ピラゾロ[3,4−d]ピリミジン化合物、その製造およびシグマリガンドとしての使用
CA3215581A1 (en) Compounds
JP2021509905A (ja) 三環性化合物、組成物及びその医薬品用途
JP7290356B2 (ja) 1,2,3,4-テトラヒドロキノキサリン誘導体、その製造方法および使用
TW202540094A (zh) 雜環羰基類衍生物調節劑、其製備方法與應用
EP4713092A1 (en) Azetidine linked bicyclic heterocyclyl compounds as ccr4 modulators
US8815870B2 (en) 4-(2-(6-substituted-hexylidene) hydrazinyl)benzonitrile and preparation thereof
KR20240021758A (ko) 시그마 리간드로서 신규 피라졸로[1,5-a]피리미딘 유도체
CN119490501A (zh) 咪唑双环化合物及其制备方法和用途
HK40085073A (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination